Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: NAI is a leading formulator, manufacturer, and marketer of nutritional supplements. Its primary activities include private-label contract manufacturing for vitamins, minerals, and herbal supplements, and the commercialization of its beta-alanine patent estate (CarnoSyn®, SR CarnoSyn®, TriBsyn™) through raw material sales and licensing. Operations are conducted primarily in Vista and Carlsbad, California, and Manno, Switzerland.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Total Net Sales | $129.9 million | $113.8 million |
| Gross Profit | $9.3 million | $6.9 million |
| Gross Margin | 7.1% | 6.0% |
| Net Loss | $(13.6) million | $(7.2) million |
| Net Loss Per Share (Basic/Diluted) | $(2.28) | $(1.23) |
| Operating Cash Flow | $5.9 million | $(1.5) million |
| Cash and Cash Equivalents | $12.3 million | $12.0 million |
| Total Debt (Line of Credit + Term Loan) | $10.8 million | $12.6 million |
| Available Borrowing Capacity | $9.9 million | $12.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% to $129.9 million. Private-label contract manufacturing sales rose 16% to $121.8 million, driven by increased orders from two major customers and new customer shipments, partially offset by lower sales from the largest customer. Patent and trademark licensing revenue declined 4% to $8.1 million due to decreased material sales.
- Profitability Decline: Despite revenue growth, the net loss widened 88% to $13.6 million. This was primarily driven by a $1.4 million legal settlement accrual (PAGA claim), a $4.8 million valuation allowance against domestic deferred tax assets, and underutilization of factory capacity.
- Margin Expansion: Gross profit margin improved by 1.1 percentage points to 7.1%, attributed to a favorable change in product sales mix, though offset by increased manufacturing overhead.
- Customer Concentration: The top three customers accounted for approximately 59% of consolidated net sales in 2025, down from higher concentrations in prior periods. The largest single customer represented 33% of sales in 2025 compared to 42% in 2024.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a net loss in the first half of fiscal 2026, followed by net income in the second half, resulting in net income for the full fiscal 2026 year. Sales are forecast to increase significantly compared to fiscal 2025.
- Strategic Focus: Continued investment in the commercialization of the beta-alanine patent estate, specifically the new TriBsyn™ product targeting the Wellness and Healthy Aging channels. The company is also focusing on operational efficiencies and cost management.
- Legal Contingency: A tentative settlement of $1.25 million plus legal fees was reached regarding a PAGA class action lawsuit filed by former employees. The company has accrued the maximum amount and is awaiting court approval.
- Liquidity and Debt Covenants: The company was not in compliance with minimum net income and fixed charge coverage ratio covenants for the quarter ended June 30, 2025. A Sixth Amendment to the credit facility was executed on June 20, 2025, which waived prior defaults and modified covenants. However, management anticipates potential non-compliance in the first half of fiscal 2026 and is negotiating further revisions with the lender.
- Risks: Key risks include supply chain disruptions and raw material cost inflation (specifically beta-alanine), geopolitical instability affecting trade and shipping, and the expiration of key CarnoSyn® patents in July 2026.
Investor Verification Checklist
- Credit Facility Status: Verify the outcome of negotiations regarding the revised credit agreement covenants for fiscal 2026, given the anticipated non-compliance.
- Legal Settlement Finalization: Monitor the court approval process for the $1.25 million PAGA settlement to confirm the final liability.
- Patent Expiration Impact: Assess the company's strategy and revenue projections following the expiration of the primary CarnoSyn® instant-release patent in July 2026.
- Customer Diversification: Track progress in reducing reliance on the top three customers, which collectively represent nearly 60% of revenue.
- TriBsyn™ Adoption: Evaluate early sales data and market acceptance for the new TriBsyn™ product line as a growth driver.